How to Standardize Cissus quadrangularis (Hadjod) Extract: 3-Ketosteroids HPLC vs. UV, Oxalate Removal & Clinical Formulations
Why generic “20%–40% Ketosteroid” UV-Vis extracts fail clinical efficacy and renal safety standards—and how nutraceutical brands can formulate with HPLC-verified, oxalate-free asymmetric triterpenoids for bone density, cortisol control, and GLP-1 metabolic management.
- The Analytical Myth: Commercial Cissus quadrangularis extracts claiming “20% to 40% Ketosteroids” use outdated UV-Vis or gravimetric methods that falsely count generic plant sterols (β-sitosterol) and lipids. True bioactive 3-Ketosteroids and asymmetric tetracyclic triterpenoids measure at 2.5% to 5.0% via HPLC.
- The Renal & Throat Hazard: Raw Hadjod stem contains 8% to 12% needle-shaped Calcium Oxalate raphide crystals. Unrefined extracts cause severe throat irritation and increase kidney stone (hyperoxaluria) risk during 8–12 week orthopedic dosing.
- Triple Clinical Scope: Properly standardized, de-oxalated Cissus quadrangularis targets three booming categories: 1) Osteoblast bone fracture healing & osteopenia, 2) Anti-catabolic glucocorticoid (cortisol) antagonism in sports, and 3) Metabolic syndrome / lipase-inhibited weight loss.
1. What is the difference between Raw Hadjod Stem, Aqueous Extracts, and De-Oxalated Hydro-Alcoholic Cissus Extracts?
Raw Cissus quadrangularis stem powder and basic aqueous (water) extracts contain negligible lipophilic 3-ketosteroids (<0.2%) alongside hazardous levels of insoluble calcium oxalate crystals (8%–12%). Conversely, a purified hydro-alcoholic extract selectively concentrates lipophilic asymmetric triterpenoids (δ-amyrin, δ-amyrone, and onocer-7-ene-3α,21β-diol) and water-soluble stilbenes while reducing oxalates below 0.5%.
In classical Ayurveda, Asthisamharaka (Hadjod, Cissus quadrangularis L.) is processed by frying or boiling the succulent quadrangular stems in ghee or milk. Modern pharmacology explains why: the osteogenic (bone-building) and anti-glucocorticoid molecules in Hadjod are moderately lipophilic tetracyclic triterpenoids and phytogenic ketosteroids that cannot be extracted efficiently using plain water alone, whereas water extraction easily pulls out irritating oxalates and mucilage.
When procuring Cissus quadrangularis for tablets, capsules, or functional beverages, R&D leads must evaluate four distinct phytochemical fractions present in the aerial stem:
- Asymmetric Tetracyclic Triterpenoids & 3-Ketosteroids (The Primary Osteogenic & Anti-Cortisol Actives): Includes Onocer-7-ene-3α,21β-diol, δ-amyrin, δ-amyrone, and 7-oxoonocer-8-ene-3β,21α-diol. Requires targeted hydro-alcoholic extraction.
- Stilbene Derivatives & Flavonoids (The Metabolic & Anti-Inflammatory Actives): Includes Quadrangularin A, B, and C (oligomeric resveratrol dimers), piceatannol, quercetin, and kaempferol, which drive pancreatic lipase inhibition and COX-2/5-LOX downregulation.
- Iridoids & Phenolic Glycosides: 6-O-trans-cinnamoyl catalpol, which stimulates osteoblast alkaline phosphatase (ALP) differentiation.
- Calcium Oxalate Raphides (The Anti-Nutrient Contaminant): Sharp acicular crystals that must be eliminated via selective precipitation and membrane filtration during manufacturing.
| Parameter / Specification | Raw Hadjod Stem Churna / Powder | Generic “20%–40% Ketosteroid” Extract (Water / UV-Vis Grade) | Purified Dual-Spectrum Extract (≥2.5%–5% HPLC 3-Ketosteroids, Oxalate-Free) |
|---|---|---|---|
| Analytical Assay Method | None (Macroscopic identification only) | Non-specific UV-Vis / Gravimetric (Counts ubiquitous β-sitosterol & plant waxes) | Validated RP-HPLC / HPTLC (Quantifies true 3-ketosteroids, δ-amyrone & Quadrangularin A) |
| True Active Triterpenoid & Ketosteroid Content | < 0.1% to 0.25% | Often < 0.5% true ketosteroids (Heavily diluted with 30–50% maltodextrin) | ≥ 2.5% to 5.0% 3-Ketosteroids + ≥ 15% Total Asymmetric Triterpenoids |
| Calcium Oxalate Content | Dangerously High (8% to 12%); causes severe throat & GI irritation | Moderate to High (2.5% to 6.0%); unmonitored on standard CoAs | Strictly De-Oxalated (< 0.5% limit); renal-safe for 90-day orthopedic protocols |
| Stilbene (Quadrangularin A/B) Retention | Low and unbioavailable inside lignified cellulose cell walls | Degraded by high-temperature open-pan boiling | Standardized ≥ 1.0% Stilbenes & Quercetin via vacuum low-temp extraction |
| Validated Clinical Dose | 3,000 mg – 6,000 mg daily (Poor compliance, high oxalate load) | 1,000 mg – 1,500 mg daily (Inconsistent fracture callus formation) | 300 mg to 600 mg daily (Replicates human RCT bone & metabolic outcomes) |
2. How is Cissus quadrangularis absorbed and converted across biological pathways?
Oral Cissus quadrangularis bioactives follow a dual absorption pathway: water-soluble stilbenes (Quadrangularins) act luminally in the gut to inhibit digestive enzymes and absorb rapidly via enterocytes within 60–90 minutes, while lipophilic 3-ketosteroids and triterpenoids require bile-salt micellarization for lymphatic and portal uptake, reaching peak osteoblast and myocyte tissue distribution at 3 to 4 hours.
Enzymatic Lipase & Amylase Blockade
Upon dissolution in the duodenum, stilbene dimers (Quadrangularin A) and flavonoids bind competitively to pancreatic lipase, α-amylase, and α-glucosidase, reducing dietary triglyceride and starch hydrolysis by 20%–35% before systemic absorption begins.
Bile-Micelle Triterpenoid Uptake
Because asymmetric triterpenoids (δ-amyrin, onocer-7-ene diols) and 3-ketosteroids are lipophilic (LogP > 4.2), co-formulation with phospholipids or medium-chain lipids increases intestinal micellar incorporation by 3-fold, enabling rapid transport into systemic circulation.
MAPK / Runx2 Osteoblast Activation
In bone periosteum, circulating Cissus metabolites activate the p38 MAPK and Wnt/β-catenin signaling cascades, upregulating the master transcription factor Runx2 (Cbfa1). This accelerates mesenchymal stem cell differentiation into osteoblasts and boosts Osteocalcin and Type-I Collagen synthesis.
Glucocorticoid Receptor Antagonism
Phytogenic 3-ketosteroids act as selective competitive antagonists at cytoplasmic Glucocorticoid Receptors (GR) in skeletal muscle and bone—blocking cortisol-induced proteolysis (muscle breakdown) and suppressing RANKL-mediated osteoclast bone resorption without androgenic side effects.
🚨 Critical QA & Regulatory Alert: The “UV-Vis Gravimetric Fraud” & Oxalate Nephrotoxicity
1. Why “40% Ketosteroids” is Scientifically Impossible in Pure Cissus: When Indian raw material vendors issue a Certificate of Analysis claiming “20% or 40% Ketosteroids by Gravimetry/UV,” they are using an obsolete, non-specific solvent precipitation test (or colorimetric reaction with 2,4-dinitrophenylhydrazine) that measures total lipophilic extractables—including cheap soy/rice phytosterols, fatty acids, and chlorophyll. Procurement teams must specify RP-HPLC standardization to ≥2.5%–5.0% 3-Ketosteroids against authenticated reference standards.
2. Mandatory Oxalate Limit (<0.5%): Under FSSAI quality parameters, brands formulating bone supplements (which often co-contain elemental Calcium) face a severe clinical liability if they use unrefined Hadjod extract. High oxalates bind supplemental calcium in the gut (destroying calcium bioavailability) and excrete through the kidneys, triggering calcium oxalate crystalluria. Always mandate an Oxalate-Free (<0.5% Total Oxalates by Titration/HPLC) CoA.
3. What clinical indications does standardized Cissus quadrangularis cover and how?
Clinically standardized Cissus quadrangularis (300–600 mg/day) is validated across four primary indications: 1) Accelerating bone fracture callus mineralization by 33%–40%, 2) Preventing postmenopausal and osteopenic bone mineral density (BMD) loss, 3) Reducing joint pain and WOMAC scores by 31% in athletes, and 4) Driving metabolic weight loss via lipase inhibition and adiponectin upregulation.
1. Accelerated Callus Formation & Bone Mineral Density (BMD)
Standardization Required: ≥2.5%–5% HPLC 3-Ketosteroids + ≥15% Triterpenoids (500–600 mg/day).
Clinical Mechanism: Human randomized clinical trials on mandibular and long-bone fractures demonstrate that standardized Cissus extract accelerates early mucopolysaccharide and collagen synthesis in the fracture callus, shortening complete bone union time by 33% to 40% (e.g., 4 weeks vs. 6+ weeks). It simultaneously upregulates Insulin-Like Growth Factor-1 (IGF-1), Alkaline Phosphatase (ALP), and Osteoprotegerin (OPG) while downregulating RANKL, halting trabecular bone loss in osteopenic and postmenopausal women.
2. Tendon/Ligament Remodeling & Anti-Catabolic Cortisol Control
Standardization Required: ≥5% HPLC 3-Ketosteroids (400–600 mg/day).
Clinical Mechanism: In resistance-trained athletes with chronic joint pain, an 8-week clinical trial showed standardized Cissus reduced total WOMAC joint pain and stiffness scores by 31%—outperforming glucosamine/chondroitin. Mechanistically, it stimulates tenocyte proliferation and Type-I collagen cross-linking while its 3-ketosteroids blunt exercise-induced serum cortisol spikes, preventing ubiquitin-proteasome muscle catabolism during caloric deficits or overtraining.
3. Lipase Inhibition, Serotonin Satiety & Visceral Fat Loss
Standardization Required: ≥2.5% 3-Ketosteroids + ≥1.0% Quadrangularin Stilbenes (300 mg twice daily, matching CQR-300® clinical specs).
Clinical Mechanism: Double-blind placebo-controlled human trials (6 to 8 weeks at 300 mg/day) demonstrate significant reductions in body weight (4–7 kg), waist circumference, fasting blood glucose, LDL cholesterol, and C-reactive protein. It works via a triple mechanism: luminal inhibition of lipase/amylase, a 30%+ increase in plasma 5-HT (serotonin) to curb emotional/carbohydrate cravings, and upregulation of adipocyte Adiponectin.
4. Hemorrhoidal Venous Plexus & Mucosal Healing
Standardization Required: ≥2.5% 3-Ketosteroids + ≥5% Total Bioflavonoids (Quercetin/Rutin).
Clinical Mechanism: Frequently overlooked by modern formulators despite robust clinical usage, standardized Cissus acts as a potent venotonic and microvascular anti-inflammatory (inhibiting COX-2, TNF-α, and iNOS). Synergized with citrus bioflavonoids, it constricts dilated hemorrhoidal vascular plexuses, arrests acute bleeding, and accelerates anal mucosal tissue regeneration.
OsteoKeto™ Callus-Pro
Fracture Union, Osteoblast Runx2 & Osteopenia Matrix
Delivery Format: Film-Coated Bilayer Tablet (Alu-Alu Blister Pack). Because our Cissus extract is strictly de-oxalated (<0.5%), it does not chelate or block the absorption of co-formulated Calcium and Magnesium.
- De-Oxalated Cissus quadrangularis
(Std. to 5% HPLC 3-Ketosteroids & 15% Triterpenoids) 500 mg - Microcrystalline Hydroxyapatite (MCHA) / Algae Cal
(Bioavailable elemental calcium + bone matrix) 250 mg - Vitamin K2 (All-Trans MK-7, Micro-Encapsulated)
(Activates Osteocalcin to bind calcium into bone) 90 mcg - Vitamin D3 (Plant Lichen Cholecalciferol)
(Intestinal calcium transport cofactor) 1000 IU - Magnesium Bisglycinate + Zinc Picolinate
(Alkaline phosphatase & collagen cross-linking) 65 mg
Target Users: Orthopedic fracture recovery patients, dental implant osseointegration, postmenopausal women with osteopenia/osteoporosis, and geriatric bone care.
MetaboCiss™ Lipo-Block
Carb/Lipase Blockade, Serotonin Satiety & Visceral Fat
Delivery Format: HPMC Veg Capsule (Taken 30 mins pre-meal). Engineered as a natural, non-stimulant metabolic & satiety companion for visceral weight management and GLP-1 support protocols.
- Dual-Std. Cissus quadrangularis Extract
(Std. to 3% 3-Ketosteroids + 1.5% Quadrangularins) 300 mg - Dichrostachys glomerata / White Kidney Bean
(Phaseolamin α-amylase starch blocker) 250 mg - Berberine HCl (Phytosomal Dispersion)
(AMPK activator & insulin sensitivity booster) 200 mg - Chromium Picolinate (USP Grade)
(Curbs postprandial glycemic spikes) 200 mcg - Ceylon Cinnamon Bark Extract (Std. Polyphenols)
(GLUT-4 translocation & gastric emptying) 100 mg
Target Users: Adults with metabolic syndrome, stubborn visceral belly fat, emotional carb-cravers, PCOS insulin resistance, and users transitioning off GLP-1 agonists (preventing muscle/bone loss).
TendonFlex™ Anti-Cort
Ligament Collagen Remodeling & Cortisol Blocker
Delivery Format: 5g Effervescent / Instantized Recovery Drink Sachet (Zesty Alphonso Mango Flavor). Completely free of oxalate throat-burn, designed for post-training consumption.
- Water-Dispersible Cissus Extract
(Std. to 5% HPLC 3-Ketosteroids, Oxalate-Free) 600 mg - Bioactive Tendon Collagen Peptides
(Specific 5 kDa peptides for tenocyte signaling) 3000 mg - Boswellia serrata (Std. ≥30% AKBA, Low β-BA)
(5-LOX & MMP-3 cartilage protection) 150 mg - Undenatured Type-II Collagen (UC-II® Equiv.)
(Oral tolerance immune joint modulation) 40 mg - Vitamin C + Manganese Gluconate
(Prolyl-4-hydroxylase tendon cross-linking) 100 mg
Target Users: Strength athletes, runners with Achilles/patellar tendinopathy, CrossFit/MMA competitors managing high cortisol and joint wear, and sports physiotherapy clinics.
4. What is the commercial scope of standardized Cissus quadrangularis in the Indian nutraceutical market?
Why Upgrading from Crude Hadjod to Oxalate-Free HPLC Cissus is a Massive Indian Market Opportunity
In India, Cissus quadrangularis (Hadjod) already enjoys 100% prescription familiarity among orthopedic surgeons, dentists, and Ayurvedic practitioners. Yet, almost every commercial brand on Indian pharmacy shelves uses crude, high-oxalate water extracts combined with cheap calcium carbonate—leading to poor patient compliance, gastric distress, and sub-clinical dosing.
Four high-margin commercial opportunities await Indian D2C brands and pharmaceutical companies that upgrade to HPLC-verified, de-oxalated standardization:
- The GLP-1 Companion & Sarcopenic Obesity Wave (2026+ Trend): As rapid weight-loss therapies surge across urban India, clinicians face a critical side effect: loss of lean muscle mass and bone mineral density (osteosarcopenia) during rapid weight reduction. Because standardized Cissus simultaneously inhibits pancreatic lipase, preserves bone density via Runx2, and blocks cortisol-driven muscle catabolism, it is the single best botanical for “Muscle & Bone-Preserving Weight Management” formulas.
- Disrupting the ₹3,500+ Crore Indian Orthopedic Rx-to-OTC Market: Medical representatives detailing an “Oxalate-Free, Renal-Safe, HPLC-Verified 5% 3-Ketosteroid Hadjod + K2-MK7” tablet have an immediate, undeniable clinical differentiator for orthopedic surgeons who worry about kidney stones when prescribing long-term calcium + Hadjod combinations.
- Booming Sports Nutrition & Running Culture: India’s marathon, gym, and pickleball/badminton boom has created an epidemic of tendonitis and rotator cuff/knee injuries among 25-to-50-year-old professionals. While Glucosamine is outdated and slow, Cissus + AKBA + Tendon Peptides delivers clinically noticeable relief in 2 to 4 weeks.
- 100% FSSAI Schedule IV Compliant & Domestic Cost Advantage: Cissus quadrangularis stem is explicitly permitted under FSSAI Nutraceutical regulations (300–1000 mg extract range). Sourcing indigenous Indian biomass and refining it via Aspkom’s de-oxalation protocol yields a world-class export-grade ingredient at highly competitive Indian manufacturing economics.
5. Frequently Asked Questions (B2B R&D & Formulation FAQ)
Answer: Standard market extracts cannot be used in liquids or powders because needle-like calcium oxalate raphides lodge in the pharyngeal mucosa, causing an intense burning and itching sensation. However, when processed through Aspkom Formula Labs’ de-oxalation and aqueous dispersion protocol (<0.5% oxalates), the extract is completely free of throat acridity and blends smoothly into flavored sachets and RTD shots.
Answer: No. Despite the historical chemical misnomer “ketosteroids,” the active compounds in Cissus quadrangularis are phytogenic asymmetric tetracyclic triterpenoids (δ-amyrin, onocer-7-ene diols). They do not bind to human androgen or estrogen receptors and do not alter serum testosterone or estrogen levels. Instead, they act selectively as glucocorticoid (cortisol) receptor antagonists and osteoblast signaling activators.
Answer: Under FSSAI Health Supplements and Nutraceuticals regulations (Schedule IV), Cissus quadrangularis aerial part/stem is permitted at 3,000 mg to 6,000 mg as raw powder, or 300 mg to 1,000 mg per day as a standardized extract, making a 300 mg BD (twice daily) or 500 mg OD (once daily) clinical dose 100% compliant for Indian retail and practitioner channels.
Ready to Commercialize Oxalate-Free, HPLC-Verified Cissus Formulations?
Partner with Aspkom Formula Labs for de-oxalated (<0.5%) Cissus quadrangularis sourcing, RP-HPLC 3-Ketosteroid & Stilbene testing, bilayer tablet compression, and turnkey FSSAI/GMP contract manufacturing.
Request R&D Samples, HPLC CoA & Commercial Quote (10k MOQ) →TURN RESEARCH INTO A DEVELOPMENT BRIEF
Working on a nutraceutical product?
Discuss the product category, formulation questions and project stage. The next step should be based on your requirements and the scope of support needed.
